Search hospitals > North Carolina > Kinston
Vidant Oncology-Kinston
Claim this profileKinston, North Carolina 28501
Global Leader in Lung Cancer
Global Leader in Breast cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Pancreatic Cancer
115 reported clinical trials
1 medical researcher
Summary
Vidant Oncology-Kinston is a medical facility located in Kinston, North Carolina. This center is recognized for care of Lung Cancer, Breast cancer, Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. Vidant Oncology-Kinston is involved with conducting 115 clinical trials across 247 conditions. There are 1 research doctors associated with this hospital, such as Misbah U. Qadir.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Clinical Trials running at Vidant Oncology-Kinston
Lung Cancer
Multiple Myeloma
Prostate Cancer
Pancreatic Cancer
Oropharyngeal Carcinoma
ALK Gene Rearrangement
Chronic Lymphocytic Leukemia
Cutaneous Melanoma
Cancer
Oral Squamous Cell Carcinoma
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Vidant Oncology-Kinston?
Vidant Oncology-Kinston is a medical facility located in Kinston, North Carolina. This center is recognized for care of Lung Cancer, Breast cancer, Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. Vidant Oncology-Kinston is involved with conducting 115 clinical trials across 247 conditions. There are 1 research doctors associated with this hospital, such as Misbah U. Qadir.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.